TEF was previously reported to retard bladder cancer cell growth by inhibiting G1/S transition and regulating AKT/FOXOs signaling, which are both closely related to glycolysis/gluconeogenesis homeostasis [43–45]. The gene discussed is TEF; the disease is urinary bladder cancer.